In last trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 9.92 million shares changing hands with its beta currently measuring 0.52. Company’s recent per share price level of $3.8 trading at $0.12 or 3.26% at ring of the bell on the day assigns it a market valuation of $1.13B. That closing price of ABCL’s stock is at a premium of 0.79% from its 52-week high price of $3.77 and is indicating a premium of 50.26% from its 52-week low price of $1.89.
For AbCellera Biologics Inc (ABCL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Upright in the green during last session for gaining 3.26%, in the last five days ABCL remained trading in the green while hitting it’s week-highest on Wednesday, 06/25/25 when the stock touched $3.8 price level, adding 7.09% to its value on the day. AbCellera Biologics Inc’s shares saw a change of 31.03% in year-to-date performance and have moved 21.79% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of 92.89% in past 30-days.
Wall Street analysts have assigned a consensus price target of 23.5 to the stock, which implies a rise of 83.83% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 34. It follows that stock’s current price would drop -31.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -31.58% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -107.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -10.77% while estimates for its earnings growth in next 5 years are of 0.83%.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
BAKER BROS. ADVISORS LP is the top institutional holder at ABCL for having 27.53 million shares of worth $81.48 million. And as of 2024-06-30, it was holding 9.3556 of the company’s outstanding shares.
The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 21.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4472 of outstanding shares, having a total worth of $64.86 million.
